See more : Welsbach Technology Metals Acquisition Corp. (WTMA) Income Statement Analysis – Financial Results
Complete financial analysis of Intelligent Bio Solutions Inc. (INBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intelligent Bio Solutions Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Nelnet, Inc. (NNI) Income Statement Analysis – Financial Results
- M.Yochananof and Sons (1988) Ltd (YHNF.TA) Income Statement Analysis – Financial Results
- Samsung Card Co., Ltd. (029780.KS) Income Statement Analysis – Financial Results
- TMC the metals company Inc. (TMC) Income Statement Analysis – Financial Results
- Catalyst Media Group plc (CMX.L) Income Statement Analysis – Financial Results
Intelligent Bio Solutions Inc. (INBS)
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.69M | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 45.81% | 25.99% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.67M | 507.42K | 3.85M | 4.27M | 588.21K | 3.18M | 2.53M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 139.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K |
| SG&A | 9.26M | 8.03M | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 173.00K |
| Other Expenses | 776.50K | 0.00 | -437.15K | -947.41K | -188.74K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 8.76M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Cost & Expenses | 13.39M | 9.69M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Interest Income | 84.82K | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 | 151.28K |
| Interest Expense | 167.14K | 223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K | 0.00 |
| Depreciation & Amortization | 1.20M | 966.73K | 8.34M | 5.21M | 2.60M | 5.83M | 4.60M | 188.72K |
| EBITDA | -8.81M | -9.47M | 30.83K | -1.82M | -561.19K | -1.50M | -416.92K | -151.28K |
| EBITDA Ratio | -283.14% | -593.55% | 0.00% | -361.23% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | -6.73M | -4.60M | -173.00K |
| Operating Income Ratio | -330.46% | -1,002.11% | 0.00% | -281.42% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 92.24K | 1.93M | 2.90K | -1.71M | -457.75K | -664.84K | -453.31K | -138.67K |
| Income Before Tax | -10.19M | -10.66M | -8.33M | -8.52M | -3.16M | -7.39M | -5.06M | -311.67K |
| Income Before Tax Ratio | -327.50% | -848.50% | 0.00% | -430.15% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 190.70K | -27.93K | 2.50M | 550.26K | -57.69K | -36.39K | -167.01K |
| Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M | -7.34M | -5.02M | -340.01K |
| Net Income Ratio | -326.40% | -845.89% | 0.00% | -355.33% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| EPS | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| EPS Diluted | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| Weighted Avg Shares Out | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
| Weighted Avg Shares Out (Dil) | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
Intelligent Bio Solutions Secures 8 New Customers with a Combined Workforce of Over 10,000 Employees Two Months into Product Launch in Australia
Why Is Intelligent Bio Solutions (INBS) Stock Down 48% Today?
7 Penny Stocks To Watch With Big News In February; Time To Buy?
7 Top Penny Stocks To Watch With Big News This Week
The Benefits of Short Term Trading Penny Stocks
These Tips Could Make You Money With Penny Stocks
Why Is Intelligent Bio Solutions (INBS) Stock Up 363% Today?
Source: https://incomestatements.info
Category: Stock Reports